to improve rna delivery, we present a protocol to produce an rna carrier based on a Zn(II)-dipicolylamine (Zn-Dpa) analog, which is an artificial receptor for phosphate anion derivatives. We further functionalized this Zn-Dpa analog to hyaluronic acid (Ha)-based self-assembled nanoparticles (Ha-nps) with a hydrodynamic diameter of 100 nm by conjugating aminefunctionalized Zn-Dpa molecules onto the Ha-nps through amide formation, resulting in efficient tumor-targeted delivery of rnas (sirnas, mirna or other short oligoribonucleotides) and small-molecule drugs. the functional group of Zn-Dpa can be converted into other groups such as a carboxylic or thiol group, and the Dpa analog can be covalently attached to a variety of existing and novel platforms or formulations for the development of multifunctional materials via standard bioconjugation techniques. protocols for rna formulation and delivery into tumor tissues and tumor cells are also described. our design strategy offers a versatile and practical method for delivering both rna and chemotherapeutics to tumor cells and expands existing nanomaterial capabilities to further the field of drug and gene delivery.
IntroDuctIon
RNAi technology has emerged as a new gene therapy approach and revolutionary tool for experimental biology [1] [2] [3] . However, the delivery of RNA molecules (e.g., siRNA, miRNA or oligonucleo tide) to a target still remains one of the biggest challenges in clini cal translation and practical applications, even though it has been over a decade since Dr. Inder Verma proclaimed "There are only three problems in gene therapy: delivery, delivery and delivery" 4 . Although many carrier systems, such as cationic polymers, lipids or amino acids, have been developed to deliver RNAs into cells with promising results, the development of safe and versatile plat forms for efficient RNA delivery is still a daunting task 5, 6 .
The most commonly used synthetic RNA carriers are based on polycations, such as polyethylene imine, polyllysine and lipidlike particles with positively charged head groups (e.g., Lipofectamine 2000 or Lipofectamine RNAiMAX) 7, 8 . Polycation systems can induce nanosized polyelectrolyte com plexes with negatively charged RNAs by electrostatic interactions. Unlike plasmid DNA, which forms stable and condensed com plexes with cationic agents, RNA loosely binds to cationic mol ecules owing to its low charge density and molecular weight 9 . Strong cationic polymers or high doses of lipids can be used to increase RNA stability; however, undesirable side effects such as increased cellular toxicity and nonspecific accumulation induced by positive charges limit their therapeutic applications.
Here we describe a highly flexible protocol to design a sophis ticated RNA carrier that we used for tumortargeted RNA deliv ery in our previous studies, which is distinct from the reported gene delivery systems that are based on cationic derivatives or chemically modified RNAs 10, 11 . This is an alternative RNA deliv ery system based on the use of ZnDPA analog, an artificial receptor for phosphate anion derivatives. We and others have reported a series of fluorescent chemosensors for the detection of phosphatecontaining molecules based on ZnDPA analogs owing to the selective ZnDPAcoordinated interaction associ ated with phosphate groups [12] [13] [14] [15] . Similar ZnDPA analogs were also used as probes for necrotic and apoptotic cells by target ing anionic phosphatidylserine on cell surfaces 16, 17 . Recently, we applied ZnDPA analogs as carriers for the delivery of therapeutic molecules, such as siRNA, using the selective and strong binding of ZnDPA with the phosphodiester groups on the siRNA back bone 10, 11 . In particular, this ZnDPA platform for RNA delivery is highly flexible and can be used in conjunction with existing delivery systems such as NPs, polymers, proteins and antibodies by simply labeling the smallmolecule ZnDPA by established bioconjugation chemistry.
Sophisticated NPs developed for therapeutic or diagnostic applications [18] [19] [20] act as highly efficient drug delivery carriers and/or imaging probes; however, many of these systems lack RNAbinding capability and cannot be readily applied for RNA delivery. To overcome the difficulty of incorporating RNA into a sophisticated NP platform, we examined our recently developed, nontoxic, tumor cell-specific, drugloadable and biodegradable HAbased selfassembled NPs for tumor therapy and imaging [21] [22] [23] . These are ideal nanoformulations for anticancer smallmolecule delivery, as the NPs can target tumor cells by active targeting of CD44, which is overexpressed on the surface of a variety of tumor cells 24, 25 . As a proof of principle, we demonstrated that a combination of the ZnDPA analog and HAbased polymeric NPs allows efficient RNA delivery through high RNA binding affinity while maintaining the unique properties of NPs, such as high cellular delivery, drugloadability and tumor targetability, as well as tumorcell permeability 11 . The versatile NP system can deliver RNAi therapeutics along with chemotherapeutics to target sites such as tumor cells. In addition, the nanocarrier can release both payloads in the tumor cells in a controlled manner. These nanoformulations carrying the RNAdrug combinations hold great potential given that they can provide a highly potent, yet less toxic, means of cancer treatment by compensating for each other. This would consequently result in synergistic therapeutic efficacy with relatively low side effects. For instance, RNA can sensitize specific cancer cells (e.g., drugresistant cancer cells) to chemotherapeutics, so that the same amount of drug molecules can kill more cancer cells than conventional chemotherapeu tics 26, 27 . The nanocarrier system also has the potential to regu late cancer metastasis when specific RNAi therapeutics related to cancer metastasis are coadministrated with chemotherapeutics by RNAdrug codelivery nanocarrier systems 28 .
Furthermore, synthesis of the DPAfunctionalized polymeric NPs is easy to scale up with costeffective and readily available chemicals, which is a key issue in the development of practical applications. Because of its flexibility and ease of preparation, sophisticated and tailored carrier systems can be designed not only for siRNA but also for other phosphate anion-containing derivatives such as miRNA or oligonucleotide analogs.
In this protocol, we describe the detailed procedures for (i) synthesizing DPApolymeric NP conjugate, (ii) formulat ing RNA complex, and (iii) delivering RNA into tumor tissues and tumor cells. Although we focus on the applications of DPA functionalized HANPs for siRNA or miRNA delivery, which were developed in our previous study, potential designs for other DPA functionalized NPs will be discussed in the Experimental design. Overall, this protocol will provide scientists with a practical tool to incorporate RNA delivery function to existing carrier systems for the development of multifunctional RNA carriers and to over come technical obstacles of typical genetic delivery agents.
Experimental design
The design concept of this protocol is to add an RNA delivery function to NPs that can deliver smallmolecule drugs by sim ple labeling of an artificial phosphate receptor, a ZnDPA analog (Fig. 1) . The NP formula does not use highly cationic polymers, and it does not require expensive chemical modifications of RNA molecules. Because NPs and macromolecules labeled with small DPA moieties will gain the ability to bind RNAs, one can eas ily transform novel NPs to RNA carriers while maintaining the unique physicochemical properties of the original NP system, e.g., cellpenetrating, tumortargeting, drugloading and opti cal or magnetic characteristics 23, 29, 30 . ZnDPA analogs can be modified with an appropriate terminal functional group such as a primary amine, carboxylic or thiol group, depending on the material to be labeled. This bioconjugation technique is similar to labeling fluorescent dyes to a protein.
Although ZnDPA analogs are small molecules compared with the relatively largesized NPs, the addition of ZnDPA may still influence the solubility or stability of NPs. Therefore, formula optimization may still be required to achieve the best possible results. In this section, we discuss the design of DPA analogs and the coupling of these molecules with NPs. Once ZnDPA decorated NPs are prepared, RNAs can be loaded and routinely tested similarly to typical RNA delivery agents. Therefore, we will not discuss the general design strategies for RNA formulation or delivery in cells, but we will provide detailed instructions in the PROCEDURE section. It is important to recognize that the protocol introduced here uses a nanomaterial and details many steps outside the synthesis of the DPA compound.
DPA analogs. Preparation of appropriate DPA analogs is the key to successful application of this protocol. It is well reported that rationally designed ZnDPA complexes are highly selective for phosphatecontaining biomolecules in aqueous solution through specific bindings between the coordinated ZnDPA complexes and the anionic phosphate groups.
In this protocol, we used bisDPA, 3, as a modelbinding ligand for RNA (Fig. 2) . 3 contains a primary amine group that can be easily conjugated to materials containing carboxylic groups via conven tional carbodiimide chemistry, 1ethyl3(3dimethylaminopropyl) carbodiimide (EDC) or N,N′dicyclohexylcarbodiimide (DCC) in the presence of Nhydroxysuccinimide (NHS). Here we introduce a bisDPA with a primary amine group. This functional group can be converted into other groups such as a carboxylic or thiol group by established methods depending on the materials to be labeled by DPA molecules. This compound is currently not commercially available and therefore requires synthesis in the laboratory. We provide a detailed synthetic protocol for the DPA analog, and if synthesis of this compound is not directly accessible in biological laboratories, an organic chemistry or polymer science group can assist in reproducing zincDPA and nanocarriers.
Zn-DPA-functionalized NPs. Once the DPA analog is synthe sized, it can be conjugated to nanomaterials through relatively easy bioconjugation methods 31 . These techniques, which are used to form linkages between NPs and functional moieties such as bisDPA, have been well developed by using commercially available chemical mediators or crosslinkers in buffers and/or organic solvents followed by purification to remove unreacted DPA analogs and reactants. As DPA is a small molecule, the unre acted amount can be removed by conventional methods using dialysis tubes, centrifugal filtration, ultrafiltration, sizeexclusion columns or disposable desalting columns depending on the type of nanomaterials. Chelated Zn ions in the DPA analog have a cru cial role in coordination between DPA and RNA. In this protocol, Zn ions are incorporated after preparation of the DPApolymeric NP conjugate. It is also important to ensure that Zn ions are well incorporated into the DPA analog, as the release of free Zn ions can induce cellular toxicity. In addition to applying DPA molecules into polymeric NPs or biomolecules, other inorganic NPs or materials can be functional ized with DPA molecules to create multifunctional siRNA carriers. As mentioned above, the endfunctional group of DPA can be modified to a thiol group. The thiolated DPA allows for the ease of labeling the surface of gold NPs or quantum dots. Alternatively, DPA analogs can be labeled onto the surface of NPs through bifunctional linkers with PEG groups to improve the stability of the particles. For further potential applications, DPA functionality can be conjugated to polymercoated, watersoluble magnetic NPs for magnetofection applications 32 . DPA molecules can also be functionalized onto materials such as carbon nanotubes, graphene sheets or gold nanocages for multifunctional roles, such as photodynamic therapy 33 , while also delivering therapeutic RNAs. As discussed, various novel agents and/or carriers can be designed by adding an RNA delivery function to existing organic or inor ganic materials without complex modification processes. In this protocol, we demonstrate how to add siRNA delivery function to our recently developed HANPs, overcoming the initial limitation relating to the highly anionic nature of the HA polymer.
Zn-DPA-functionalized HA-NPs. We exploit HANPs, as they are nontoxic, highly tumor cell-permeable, drugloadable, bio degradable, easy to formulate and cost effective to manufacture. An amphiphilic HA conjugate can be prepared by coupling a hydrophilic biopolymer HA with a hydrophobic bile acid ana log: 5βcholanic acid (5βCA; Fig. 3) . In aqueous conditions, the amphiphilic HA conjugate readily forms selfassembled NPs by a sonication method. HANPs can efficiently accom modate hydrophobic smallmolecule drugs in the hydrophobic inner core. Moreover, the nanocarrier system shows excellent tumor cell targetability and permeability. HANPs can recognize and actively endocytose tumor cells, given that a variety of tumor cells are known to overexpress HA receptors, e.g., CD44 (refs. 24,25) . Once HANPs penetrate tumor cells, the HA back bone is rapidly degraded by the HAdegrading intracellular enzyme hyaluronidase1 (refs. 23,34) , which substantially accel erates drug release in tumor cells 23 . We integrate the synthetic receptor, ZnDPA, with the tumorhoming NPs into a nanocarrier system. Because HA has multiple functional groups including car boxylic and hydroxyl groups on its backbone, HANPs can be easily modified with multiple DPA molecules containing amine groups through amide formation. By adding Zn 2+ salt molecules into HADPANPs (HDNPs), HADPA/ZnNP complexes (HDzNPs) can be prepared ( Fig. 4 ; thinlayer chromatography (TLC) for com pound 2 is shown in Fig. 5 ). The loading of DPA molecules onto the HA backbone can be calculated by 1 H NMR. The UVvisible absorption spectra show a very weak bisDPA absorbance and a high background absorbance in the presence of HADPA conju gates. RNAbinding capability can be tested in a retardation assay by agarose gel electrophoresis. Complexation of RNA molecules onto NPs should induce marked retardation of RNAs compared with that of free RNAs. The zetapotential of NPs also reflects RNA binding. After RNA molecules are incorporated onto NPs, zeta potential of nanoformulations should decrease in comparison with the bare NPs without RNAs. In addition to loading siRNA molecules, DPAfunctionalized NPs can bind to other molecules such as miRNAs and oligonu cleotides (Fig. 6) .
After RNA loading is optimized, comple mentary calcium and phosphate ions can be added onto the NPs (CaPHDz/RNANPs), which facilitates intracellular RNA release and endosomal escape 35 . We confirmed cellular delivery using Cy3labeled siRNA and analyzed transfection efficiency of siRNAs with model systems. Firefly luciferase (fLuc) genetargeting siRNA (siLuc) and EGFP genetargeting siRNA (siGFP) were transfected in stabilized can cer cell lines that express fLuc and GFP, 143BfLuc and DU145GFP. In addition, miRNA can also be effectively delivered with our system. We demonstrated trans fection of miR34a in HCT116 cells with a fLuc reporter vector containing the com plementary target sequences of miR34a. Cytotoxicity of NPs was evaluated by the alamarBlue cell proliferation assay.
Multicargo nanocarriers loaded with RNAs and small-molecule drugs.
To show that HDzNPs can act as a multi functional carrier for both hydrophobic drug molecules and for RNAi therapeutics, the hydrophobic anticancer drug paclitaxel (PTX) was loaded in the interior of HDzNPs as a model compound, and siRNA molecules were complexed on the surface of NPs 11 . For preclinical applications, PTX can be substituted with various other anticancer drugs such as doxorubicin or camptothecin depending on established treat ment regimens. To monitor simultaneous siRNA/drug delivery in cells, Cy3labeled siRNA and Oregon green (OG)labeled PTX were loaded onto the HDzNPs, and the NPs were then applied to CD44positive HCT116 cells. The cells were monitored by multichannel fluorescence microscopy at 30 min post treatment.
In addition, therapeutic activity of RNA/drugincorporated NPs on HCT116 cells was evaluated using a standard alamar Blue assay. Drugloaded NPs can then be associated with thera peutic RNAs, and they may show synergistic therapeutic effects induced by both small molecules and RNAi. In our initial proof ofprinciple studies 11 , we tested siRNA silencing and miR34a delivery effects of CaPHDz/siLuc and CaPHDz/miR34a in HCT116miR34a tumor xenograft mice after i.v. injection of the formulas. Silencing of the fLucencoding gene and intracellular delivery of miR34a were monitored by in vivo bioluminescence imaging (BLI). We advise that you vary the doses of RNAcontaining
NPs and image at different time points when optimizing this protocol in your setting. When anticancer drugs or therapeutic siRNAs are used instead of dye and siLuc, therapeutic effects can be investigated by monitoring tumor volume.
Overall, modification of HANPs with ZnDPA endows HANPs with a unique function to bind RNAs. Furthermore, multiple DPA molecules on HANPs may result in HDzNPs with strong RNA interaction. Unlike many other conventional RNA delivery carriers involving chemical conjugation or physical complexation of RNA with polycations, HANPs are highly biocompatible because they are based on a naturally occurring anionic biopolymer HA. Together with the excellent tumortargetability of HANPs and the distinctive loadability of RNA therapeutics onto the sur face and hydrophobic drug molecules in the core of HDzNPs by a simple mixing method, this RNA and smallmolecule drug delivery system is a promising, safe and efficient avenue for targetedgene anticancer drug therapy. • Oligonucleotide (Oligo623; Invitrogen, custom synthesis; see Table 1 • 3| Immerse a bottle of di-tert-butyl dicarbonate (melting point 22-24 °C) in a water bath at ~40 °C.
4| Take out 4.84 ml (4.6 g; density 0.95 g/ml) of di-tert-butyl dicarbonate from the bottle in a water bath at ~40 °C using a 5-ml micropipette, and transfer it to a 20-ml vial. Next, dissolve di-tert-butyl dicarbonate in the vial with 5 ml of methanol.
5| Slowly add the dissolved di-tert-butyl dicarbonate methanol solution prepared in
Step 4 into the tyramine solution prepared in Step 2. ! cautIon Gas evolution will take place.
6| Slowly add 8.3 g of K 2 CO 3 (60.0 mmol) into the solution prepared in Step 5. Next, add 10-15 ml of distilled water with a squeeze bottle carefully to dissolve K 2 CO 3 . Stir the reaction mixture for 4 h at room temperature.
7|
Check whether tyramine is completely consumed by TLC analysis. In a 10:1 (vol/vol) mixture of methylene chloride and methanol, the R f value of the product is ~0.8 and that of tyramine is negligible. Remove volatiles from the reaction mixture under low pressure using a rotary evaporator at 60 °C for 30 min.
8|
Dissolve the remaining residue in 50 ml of ethyl acetate. Transfer it to a 250-ml separatory funnel containing 100 ml of deionized water. Shake the mixture vigorously to mix well and allow it to rest for separation of the organic layer. Carefully decant the separated organic layer into a flask.
9| Add 20-30 g of Na 2 SO 4 and manually stir the flask at 100 r.p.m. for 1-2 min to remove residual water from the decanted organic layer.
10|
Filter and remove volatiles using a rotary evaporator at 60 °C for 30 min to obtain a viscous brown liquid. The expected yield is 4.0-4.5 g (85-95%).  pause poInt Compound 1 can be stored at 4 °C for several months.
synthesis of compound 2 • tIMInG 2-3 d 11| Add a Teflon-coated stir bar to a single-neck round-bottom flask (100 ml) and add 3.7 ml of 2,2′-dipicolylamine (20.56 mmol, density: 1.107 g/ml).
12| Add 1.57 ml of formaldehyde solution (21.08 mmol, density: 1.09 g/ml, 37 wt% water solution). Add 1 ml of 1 N HCl. Stir the mixed solution until the mixture becomes clear.
13| Dissolve 2.37 g of compound 1 (10.0 mmol) in ~5 ml of 1-propanol. Next, add it to the reaction mixture. Add 30 ml of 1-propanol.
14|
Attach a reflux condenser to the flask containing the reaction mixture, seal it with a septum and insert a needle with a balloon filled with N 2 gas.
15|
Stir and reflux the reaction mixture for 2-3 d. Check the products by TLC; care must be taken because of the difficulty of confirming the completion of the reaction and purifying the product (Fig. 3) . The completed reaction mixture is concentrated under low pressure using a rotary evaporator with a water bath at 60 °C to provide a dark brown mixture.  crItIcal step Check TLC to see whether Boc-protected tyramine is completely consumed. If the remaining 2,2′-dipicolylamine is negligible, terminate the reaction.
16|
Dissolve the dark brown mixture in 50 ml of methylene chloride, and transfer it to a 250-ml separatory funnel containing 100 ml of deionized water. Neutralize it with saturated aqueous K 2 CO 3 solution. Shake the mixture well.
17|
Carefully decant the organic layer into a flask. Add 20-30 g of Na 2 SO 4 into the flask and shake the flask manually for 1-2 min (~100 r.p.m.) to remove residual water.
18|
Filter and evaporate the organic solvent under low pressure using a rotary evaporator at 40 °C to obtain a sticky dark brown liquid. Dissolve the residue in a small amount of methylene chloride (2-3 ml). Load the dissolved residue onto a silica gel column (300-400 ml) filled with methylene chloride.
19|
Elute the silica gel column with 300 ml of methylene chloride. Next, elute it with 300 ml of hexane, and then elute it with 500 ml of ethyl acetate. A light yellow solution is eluted immediately. Continue until clear eluent emerges. Then elute with hexane (300 ml) again to clear off ethyl acetate from the silica gel column.
20|
Elute with a mixture of methylene chloride and methanol. Gradually increase the ratio of methylene chloride to methanol from 100:0, 100:1.0, 100:1.5, 100:2.0, 100:2.5, 100:3.0, 100:3.5, 100:4.0, 100:4.5 to 100:5. Elute with 300 ml of methylene chloride. At each ratio containing methanol, elute with a mixture of 300 ml of methylene chloride and methanol. Note that silica gel column is eluted under air pressure.
21|
Check the eluent coming out of the column by TCL periodically (~5 times per min), and when a dark spot appears on TLC under 254-nm UV light start to collect the eluent. When the dark spot on TLC seems blurred, then stop collecting the eluents.
22|
Remove volatiles from the collected eluents under low pressure using a rotary evaporator at 40 °C to provide a sticky brown liquid compound 2 (Boc-bis-DPA). The estimated yield is up to 80% (5.3 g). TLC (silica, methylene chloride:methanol = 10:1), R f = 0.5.  pause poInt Compound 2 can be stored at 4 °C for several months.
synthesis of compound 3 • tIMInG 6 h 23| Add a Teflon-coated stir bar to a single-neck round-bottom flask (250 ml).
24| Dissolve 1 g (1.5 mmol) of compound 2 in 10 ml of methylene chloride.
25|
Add dissolved compound 2 into the single-neck round-bottom flask (250 ml).
26|
While stirring, slowly add a mixture of 26 ml of methylene chloride and 4 ml of trifluoroacetic acid.
27| After 4 h, confirm the products with TLC (R f compound 2 = 0.5, R f compound 3 = 0.05, silica, methylene chloride:methanol = 10:1) and then completely remove volatiles under low pressure using a rotary evaporator at 40 °C.
28|
While stirring, dissolve the remaining residue in 20 ml of methylene chloride and add 10 ml of saturated aqueous K 2 CO 3 solution slowly to basify the mixture. ! cautIon Gas evolution will take place.
29|
Transfer the mixture to a 50-ml separatory funnel, shake it well and carefully decant the organic layer into a flask. Pour 20 ml of methylene chloride to the remaining aqueous layer in a separatory funnel. Shake it well and decant the organic layer into a flask.
30|
Dry the combined organic layer with Na 2 SO 4 . Add 10-15 g of Na 2 SO 4 into the flask and shake the flask manually for 1-2 min (~100 r.p.m.) to remove residual water. Filter and remove volatiles under low pressure using a rotary evaporator at 40 °C to obtain a gummy brown solid compound 3 (bis-DPA). Expected yield is over 95%.
? troublesHootInG  pause poInt Compound 3 can be stored at 4 °C for several months. 
32| Dry the solution prepared in
Step 31 using a rotary evaporator under aspirator vacuum to obtain compound 4 (5β-CA methyl ester, MeCA). Characterize its chemical structure using 1 H NMR in CDCl 3 at a concentration of 10 mg/ml.  pause poInt MeCA can be stored at −20 °C for several months.
synthesis of compound 5 • tIMInG 7 h plus drying time 33| Add compound 4 (0.9 g, 2.4 mmol) into a round-bottom flask (50 ml) containing EDA (6 ml, 89.7 mmol). Let the reaction occur with stirring under reflux at 130 °C for 6 h. Use a glass pipette to add the solution dropwise into a 200-ml beaker containing 100 ml of cold deionized water. ! cautIon EDA is flammable and harmful if swallowed or if it comes in contact with skin. Handle it inside a fume hood and avoid contact with skin and eyes. Use protective goggles, gloves, a mask and a lab coat.
34| Centrifuge the solution obtained in
Step 33 at 25,000g, 4 °C for 30 min and remove the supernatants. Wash the precipitates thoroughly with deionized water. Repeat the centrifuging and washing steps five times to remove residual EDA. Step 39 in a 15-ml conical tube. Add 12 ml of PB (pH 6.5). Sonicate the HA-CA solution for 20 min to prepare HA-NPs using a probe-type sonifier.
42| Dissolve EDC (10.5 mg, 54 µmol) in PB (pH 6.5, 500 µl); sulfo-NHS (17.6 mg, 81 µmol) in DMSO (500 µl); and compound 3 (bis-DPA; 15 mg, 27 µmol) in DMSO (1 ml) by agitation.
43|
Add EDC solution into the HA-NPs solution prepared in Step 41. Allow the reaction to proceed with stirring at room temperature for 30 min.
44| Add NHS and compound 3 solution into the solution prepared in Step 43. Allow the reaction to proceed overnight at room temperature.
45| Dialyze the resulting solution prepared in
Step 44 using dialysis tubing (12-14 K MWCO) against water/methanol (1 volume/1 volume) for 1 d and distilled water for an additional 1 d to completely remove unreacted EDC, NHS and DPA residues.
46|
After the dialysis step, lyophilize the solution prepared in Step 45.  pause poInt The HA-CA-DPA (HD) conjugate sample prepared in Step 46 may be stored at -20 °C for several months.
47|
Disperse the HD conjugate in ultrapure water (2 mg/ml) by sonication, as described in
Step 41, for 20 min to prepare HD-NPs. Dissolve ZNH in ultrapure water (3 mg/ml, 10.1 mM). Add Zn stock solution (5 ml) into the HD-NPs solution (5 ml). Incubate the resulting mixture at 40 °C under agitation for 20 min to prepare HA-CA-DPA/Zn NPs (HDz-NPs).
48| Freeze-dry the solution to obtain compound 7.  pause poInt Compound 7 may be stored at −20 °C for several months.
49| Characterize compound 7 using 1 H NMR after dissolving it in D 2 O/CD 3 OD (1 volume/1 volume) at a concentration of 5 mg/ml. part 4, formulation of rna therapeutics • tIMInG 1.5 h  crItIcal For co-delivery of both RNA and hydrophobic small-molecule drugs, the encapsulation step (box 2) should be followed by the siRNA/miRNA/oligonucleotide formulation step (Step 51).
50| Dissolve compound 7 (HDz-NPs) prepared in
Step 48 or the drug-loaded HDz-NPs prepared in box 2 in ultrapure water at 1 mg/ml by sonication, as described in
Step 41, for 20 min.
51| Mix 2 µl of the solution prepared in
Step 50 with 1 µl of 10 µM siRNA (luciferase siRNA: siLuc), miRNA (miR-34a) or oligonucleotide (Oligo-623; 10 pmol) by gentle vortexing. Incubate the resulting HDz/RNA-NPs at room temperature for 30 min.  pause poInt The HDz/RNA-NPs can be stored at 4 °C until it is required, but for no longer than 30 d.
52| Mix 3 µl of the solution prepared in
Step 51 with 1 µl of Tris-calcium buffer; add 4 µl of HEPES-PB and mix the solution by vigorously pipetting up and down (CaP-HDz/RNA-NPs).
 pause poInt The CaP-HDz/RNA-NPs solution can be stored at 4 °C until it is required, but for no longer than 30 d.
(v) Evaluate GFP expression levels in the DU145-GFP cells after the treatment using the flow cytometer. ? troublesHootInG Troubleshooting advice can be found in table 2. Fig. 3a,b ). An average hydrodynamic diameter of HDz-NPs is ~100 nm.
Formulation of rnas with cap-HDz-nps
In Steps 50-53, HDz-NPs readily form nanocomplexes with three kinds of RNAs, including siRNA, microRNA and oligonucleotides. The complexation of HDz-NPs with siRNA, microRNA or oligonucleotides can be confirmed by a retardation assay using agarose gel electrophoresis. The anticipated results are shown in Figure 6 . HDz-NPs are able to bind siRNA, microRNA and oligonucleotides, whereas RNA molecules can easily be released from HDz-NPs after addition of phosphate ions to the complexes. This indicates that the complexation is based on coordination between the phosphate groups of RNAs and Zn-DPA. In contrast, siLuc can be secured, even after the addition of phophate ions, on HDz/siLuc capped with complementary calcium ions or calcium phosphate ions, i.e., Ca-HDz/siLuc or CaP-HDz/siLuc, respectively; the addition of phosphate ions does not trigger siLuc release from Ca-HDz/siLuc or CaP-HDz/siLuc. It is important to note that RNA release can be markedly accelerated in acidic conditions, i.e., endosomal/lysosomal pH (pH 6 or 5). As an example, we present a typical result in 
Formulation and intracellular delivery of rnas and drugs with cap-HDz-nps
CaP-HDz-NPs should be able to accommodate both biological therapeutics (RNAs) and chemotherapeutics (small-molecule hydrophobic drugs) onto a single platform (box 2). Small-molecule drugs can be encapsulated within the hydrophobic interior of HDz-NPs owing to interaction between hydrophobic CA molecules of NPs and hydrophobic drug molecules using a sonication method in aqueous solution. Drug loading efficiency and drug contents can be quantified using an HPLC technique after the dissolution of the nanostructure in a co-solvent of distilled water and methanol (1:1 (vol/vol)). The loading efficiency should be >85%, and loading contents can vary in the range of 5-50% depending on the feeding amount of drug molecules. After hydrophobic small-molecule drugs are loaded, RNAs can be complexed as described in Steps 50-53. Cellular uptake and also colocalization of NPs, siRNA and drugs can be monitored by multichannel confocal fluorescence microscopy after treatment of HCT116 cells with the Cy5.5-labeled CaP-HDz-NPs that are loaded with both Cy3-labeled siRNA and OG-PTX (CaP-HDz/RNA+PTX). The anticipated results are shown in supplementary Figure 5 . The nanoformulations containing RNA and drug molecules can be rapidly internalized; colocalization of the three components of the nanoformulations (NPs, RNAs and drugs) should be observed in the HCT116 cells at 30 min after treatment.
In vitro rna transfection assay
At
Step 54B, the ability of CaP-HDz to deliver RNAs (siGFP, siLuc and miR-34a) can be confirmed by measuring the expression of GFP or fLuc in DU145-GFP cells, 143B-fLuc cells or HCT116-fLuc-miR34a treated with CaP-HDz/siGFP, CaP-HDz/siLuc or CaP-HDz/miR-34a nanoformulations (supplementary Fig. 6 ). Figure 7a ,b show typical results of the suppression effect of CaP-HDz/siLuc or CaP-HDz/siGFP on fLuc or GFP gene expression. Figure 7c shows the transfection effect of CaP-HDz/miR-34a on the suppression of fLuc signals in HCT116-fLuc-miR34a cells. The BLI signal intensity of untreated DU145-GFP cells, 143-fLuc cells or HCT116-fLuc-miR34a is set as the maximum GFP and fLuc expression, respectively. In the cells treated with CaP-HDz/RNAs, remarkably high gene silencing or transfection efficacy should be detected in a dose-dependent manner. The silencing efficacy of CaP-HDz/RNAs should also be superior to the Lipo2K or RNAiMAX complexes. Control Lipo2K or RNAiMAX complexed with nonspecific siNC, siRNA (siLuc and siGFP) or miR-34a should show significantly lower silencing/transfection effects.
In vivo delivery of cap-HDz complexed with sirna or mirna
Step 54C, tumor-specific, in vivo gene silencing activity of CaP-HDz/RNA nanoformulations can be confirmed by in vivo BLI. The miR-34a reporter system is based on fLuc reporter genes, and thus the reporter system can be used for a dual imaging application to assess delivery efficiency of the CaP-HDz/RNA nanoformulations complexed with siLuc or miR-34a. fLuc gene silencing and intracellular miR-34a delivery efficacy of CaP-HDz/NRA nanoformulations can be evaluated by monitoring the BLI signals from tumors of HCT116-fLuc-miR34a xenograft mice after systemic administration of RNA nanoformulations. Figure 8 shows typical in vivo BLI results to appraise the suppression effect of CaP-HDz/siLuc or CaP-HDz/miR34a. The BLI intensities from tumors of CaP-HDz/siLuc group should be decreased 24 h after injection and should be drastically dropped 72 h after injection. The tumors of the CaP-HDz/miR34a group should also show a substantial decrease in BLI signal from 24 h after injection. In contrast, The BLI intensities from tumors of control groups injected with PBS, CaP-HDz/siNC or CaP-HDz/miR-NC nanoformulations should be amplified owing to tumor growth. 
